All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

pipeline-prospector-insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Herantis Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FINLAND Finland

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

Herantis Pharma Plc Announces Topline Results of Phase 1-2 CDNF Trial

Contact the Supplier

Lead Product(s): CDNF

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 25, 2020

Details:

Topline analysis confirms positive safety and tolerability of CDNF in advanced-stage Parkinson's disease patients, with encouraging biological responses.